Results 271 to 280 of about 155,757 (387)

C-Cell Carcinoma in a Common Marmoset (Callithrix jacchus) With a Brief Review of Thyroid Neoplasms in Neotropical Primates. [PDF]

J Med Primatol
de Macêdo IL, Gottdenker NL, Oliveira LJ, de Sousa DER, da Fonseca YNG, Cerqueira LA, Borges BP, de Castro MB.   +7 more
europepmc   +1 more source

Peripheral Nerves in Cancer: Regulatory Roles and Therapeutic Strategies

MedComm, Volume 7, Issue 2, February 2026.
The interaction between cancer cells and peripheral nerves: (1) tumor cells could induce the growth of new neural axons and constructing a neural fiber network within the tumor tissue through secreting nerve growth factors; (2) nerve‐derived bioactive molecules can induce perineural invasion of tumor and regulate the malignant phenotype of tumor, such ...
Yan Fu, Zhi‐Shan Ge, Qing‐Yue Cao, Zi‐Han Li, An Zhang, Hai‐Dong Zhu, Gao‐Jun Teng   +6 more
wiley   +1 more source

Pembrolizumab in recurrent or metastatic medullary thyroid cancer. [PDF]

Oncologist
Del Rivero J, Donahue RN, Marte JL, Gramza A, Cordes L, Karzai F, Abel ML, Schlom J, Gulley JL, Madan RA.   +9 more
europepmc   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog. [PDF]

J Headache Pain
Argoff C, Khan FA, Herzog SP, Smith RM, Soni-Brahmbhatt S, Asher D, Awad SF, Grossman SW, Patel F, Buse DC.   +9 more
europepmc   +1 more source

<b>EXPRESSION OF TAU—LIKE MICROTUBULE-ASSOCIATED PROTEINS IN CALCITONIN-PRODUCING </b><b>CELLS </b>

, 1995
Ichiro Nishiyama, Tadachika Oota, Manabu Ogiso   +2 more
openalex   +2 more sources

Medullary thyroid cancer with undetectable serum calcitonin.

Journal of Clinical Endocrinology and Metabolism, 2015
E. Brutsaert, A. Gersten, Andrew B. Tassler, M. Surks   +3 more
semanticscholar   +1 more source

Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1499-1507, February 2026.
Abstract Aims Published literature has raised concerns regarding a causal association between glucagon‐like peptide 1 receptor agonist (GLP‐1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP‐1RA use.
Tina Vilsbøll, Michael Stellfeld, Vanita R. Aroda, Sune Dandanell, Jens‐Peter David, Ceyda T. P. Kristiansen, Søren Rasmussen, Fiona L. Roberts, Laszlo Hegedüs   +8 more
wiley   +1 more source

Real-world assessment of current migraine prophylaxis in Egypt: a multicenter national study. [PDF]

J Headache Pain
Al-Azayem SA, Nada MAF, Dahshan A, Moawad MK.   +3 more
europepmc   +1 more source

Canoe full of hot paddlers: TRPV1 neurons steering cardiorespiratory control

The Journal of Physiology, EarlyView.
Richard J. A. Wilson, Nicholas Jendzjowsky   +1 more
wiley   +1 more source